Lung most cancers dominates ASCO social media dialog amongst well being care professionals


We had been unable to course of your request. Please attempt once more later. Should you proceed to have this concern please contact [email protected].

Dialogue about lung most cancers analysis breakthroughs dominated the social media dialog amongst well being care professionals throughout this yr’s ASCO Annual Assembly.

Creation Healthcare, a number one digital insights consultancy, used its CREATION Pinpoint expertise to trace 37,000 posts by greater than 3,000 HCPs between Might 31 and June 4.

Topics of social media discussion among HCPs during ASCO

A Creation Healthcare evaluation recognized greater than 4,000 particular person social media posts amongst HPCs that made reference to lung most cancers, considerably greater than every other most cancers sort. Picture: Creation Healthcare

The evaluation recognized greater than 4,000 particular person posts that made reference to lung most cancers — considerably greater than every other most cancers sort.

A big proportion of this HCP dialogue centered on responses to outcomes of a number of transformative trials offered on the convention. It additionally included dialog highlighting the rising significance of biomarker evaluation, genomic profiling, and the advantages of telehealth and palliative care.

HCPs used the hashtag #lcsm — that means “lung most cancers social media” — 1,968 occasions. They used #lungcancer 595 occasions.

Follow-changing trials

Creation Healthcare’s evaluation confirmed the outcomes of main trials — significantly these in lung most cancers — drove a lot of the social media dialog amongst HCPs throughout ASCO.

Graphic that shows how major trials sparked social media conversation during ASCO 

Outcomes of a number of main trials sparked conversations amongst HCPs on X throughout ASCO Annual Assembly. Picture: Creation Healthcare.

The randomized part 3 LAURA trial — which confirmed osimertinib (Tagrisso, AstraZeneca) following chemotherapy improved PFS in contrast with placebo amongst sufferers with superior EGFR-mutant non-small cell lung most cancers — was probably the most steadily talked about trial throughout ASCO. It accounted for greater than 900 particular person mentions by HCPs.

Suresh S. Ramalingam, MD, offered the LAURA trial findings throughout ASCO’s plenary session and obtained what one on-line HCP described as a “rousing ovation” from the group.

HCPs’ instant responses praised the “huge” and “spectacular” PFS advantages of the therapy. Others labeled the trial as “follow altering,” “thoughts blowing” and a “large win for sufferers.”

Some HCPs, nevertheless, expressed concern in regards to the lack of mature OS information. A small quantity additionally feared that there might have been an under-staging of a major proportion of sufferers within the placebo group, resulting in a doubtlessly inflated disparity in PFS outcomes between osimertinib and placebo.

Dialogue on the entire, nevertheless, was overwhelmingly optimistic. A number of HCPs prolonged congratulations to the staff concerned within the trial.

Creation Healthcare’s evaluation confirmed equally optimistic conversations surrounding two different lung most cancers trials offered at ASCO.

The randomized part 3 ADRIATIC trial — which confirmed durvalumab (Imfinzi, AstraZeneca) improved outcomes for sufferers with limited-stage small cell lung most cancers after customary chemoradiotherapy — accounted for 482 posts by HCPs.

Charu Aggarwal, MD, Leslye M. Heisler assistant professor for lung most cancers excellence at College of Pennsylvania’s Perelman College of Medication and a Healio | HemOnc At this time Affiliate Medical Editor — described the trial information as “really historic” and instructed the routine is a “new customary of care.”

Graphic showing trials that sparked social media conversation during ASCO 

Trials from a number of most cancers sorts sparked social media dialog amongst HCPs throughout ASCO Annual Assembly. Picture: Creation Healthcare.

The evaluation recognized 465 social media posts by HCPs in regards to the randomized part 3 CROWN trial, which confirmed lorlatinib (Lorbrena, Pfizer) improved PFS in contrast with crizotinib (Xalkori, Pfizer) amongst adults with superior anaplastic lymphoma kinase-positive NSCLC.

Oncologist Giannis Mountzios, MD, stated the research “units a brand new benchmark in precision oncology.”

Marcelo Corrassa, MD, stated a “key takeaway” from the trial information — given the novelty of a 60-month PFS in NSCLC — ought to be for physicians to do a “higher job making the lives of our sufferers higher.”

One oncologist instructed utilizing dynamic monitoring to establish sufferers who don’t profit from lorlatinib use.

Different most cancers sorts

Though lung most cancers accounted for 3 of the highest 5 most-discussed trials throughout ASCO, analysis from different subspecialties additionally helped drive the social media dialog.

The Creation Healthcare evaluation confirmed the ESOPEC trial was the second-most mentioned trial throughout ASCO.

The trial — talked about greater than 800 occasions by on-line HCPs — in contrast two methods for regionally superior esophageal adenocarcinoma that could possibly be handled with surgical procedure: the CROSS protocol (chemoradiotherapy earlier than surgical procedure) and the FLOT protocol (chemotherapy earlier than and after surgical procedure).

Benedikt Westphalen, MD, stated the outcomes would set up a “new customary of care.”

Others, nevertheless, appeared not totally satisfied, questioning why OS outcomes had been “unexpectedly poor” with CROSS and suggesting that chemoradiotherapy was an outdated comparator.

Creation Healthcare recognized greater than 3,000 posts on social media by HCPs throughout the convention that mentioned breast most cancers, the second most-discussed most cancers sort.

Subjects of curiosity included a brand new blood check to foretell most cancers recurrence and first-line remedies for HER2-positive breast most cancers,

The hashtag #bcsm — that means “breast most cancers social media” — was used 684 occasions, and #breastcancer was used 561 occasions.

Genitourinary most cancers — together with bladder, kidney and prostate cancers — was the third most-discussed matter.

On-line HCPs mentioned optimistic outcomes with drug combos — together with toripalimab (Loqtorzi, Coherus Biosciences) and disitamab vedotin (Pfizer) for bladder most cancers. Additionally they highlighted biomarker information from the CheckMate -901 trial and praised synthetic intelligence digital histology for predicting prostate most cancers recurrence and metastasis.

AI and telehealth in oncology

Creation Healthcare’s evaluation additionally confirmed numerous references to the function of synthetic intelligence in oncology.

In 401 posts, HCPs acknowledged the transformative function of AI in figuring out biomarkers for prognosis or predicting therapy outcomes in numerous most cancers sorts, together with colorectal most cancers and prostate most cancers.

They shared highlights from schooling classes that explored using AI in most cancers analysis, and so they famous how AI can bridge communication gaps to boost patient-practitioner relationships.

The evaluation revealed 555 posts from HCPs suggesting telehealth companies are as efficient as in-person supply of palliative look after sufferers with superior lung most cancers and might help guarantee supply of “high-quality most cancers care in rural areas.”

Most engaged HCPs

Utilizing CREATION Pinpoint expertise, Creation Healthcare recognized probably the most peer-engaged HCPs all through ASCO.

The three most profitable had been Toni Okay. Choueiri, MD, who garnered greater than 2,000 engagements from friends by way of the convention; Sumanta Okay. Pal, MD, FASCO, who obtained 1,523 engagements; Narjust Florez, MD, FASCO, who obtained 1,517 engagements.

Graphic showing most peer-engaged HCPs during ASCO 

The three most engaged HCPs on-line throughout ASCO Annual Assembly had been Toni Okay. Choueri, MD; Sumanta Okay. Pal, MD, FASCO; and Narjust Florez, MD, FASCO. Picture: Creation Healthcare.

Choueiri, director of Lank Heart for Genitourinary Oncology at Dana-Farber Most cancers Institute, was the most-mentioned HCP by friends on-line. He was tagged in 2,162 posts that praised him for his analysis shows, mentorship function and management nominations.

Choueiri posted 134 occasions throughout ASCO, primarily sharing outcomes of GU most cancers trials and celebrating friends for his or her analysis shows.

His most engaged submit, which garnered 242 likes, congratulated Lynn Schuchter, MD, for her president’s tackle throughout ASCO’s opening session.

Pal — chair of the kidney and bladder most cancers illness staff at Metropolis of Hope and a Healio | HemOnc At this time Editorial Board member — was the second most talked about HCP by friends on-line. He was tagged in 1,523 posts, lots of which counseled him for his speak on managing variant histologies in urothelial and renal cell cancers. Others reshared posts from Pal by which he praised colleagues.

Pal posted 307 occasions throughout ASCO, typically sharing outcomes of genitourinary most cancers trials and congratulating friends for his or her contributions.

Florez — affiliate director of the Most cancers Care Fairness Program and thoracic medical oncologist at Dana-Farber Brigham Most cancers Heart, assistant professor of drugs at Harvard Medical College and a Healio Ladies in Oncology Peer Perspective Board member — was the third most talked about HCP by friends on-line.

She was tagged in 1,517 posts, lots of which congratulated her for turning into the youngest ASCO fellow, being acknowledged within the “40 Underneath 40 in Most cancers” class of 2024, and for the lung most cancers analysis she offered.

Florez posted 401 occasions throughout ASCO, sharing highlights from classes she loved and lung most cancers analysis that she or her colleagues offered.

In her most engaged submit, which garnered 127 likes, she expressed her gratitude for being an affiliate editor with JAMA Oncology.

‘A novel alternative’

“Listening to the net conversations of well being care professionals throughout probably the most important worldwide well being conferences like ASCO 2024 is immensely precious,” Creation Healthcare CEO Daniel Ghinn stated. “It permits us to take a deep dive into the ideas, views, opinions and underlying sentiments of well being care professionals towards among the strongest breakthroughs in most cancers therapy of our era. It’s evident that many upcoming therapy choices, as well being care professionals themselves be aware, have the potential to utterly revolutionize most cancers look after sufferers.”

“This yr, our findings spotlight lung most cancers — and significantly current medical trials within the area — as probably the most important space of debate,” Ghinn added. “The dialogue surrounding the advantages, drawbacks, challenges and options of every therapy choice offers precious insights into how frontline healthcare employees understand their potential impacts. Listening to those conversations gives a singular alternative to grasp the priorities and views of well being care professionals. This understanding is essential for bettering the supply of healthcare world wide.”


Charu Aggarwal, MD, MPH, FASCO. @CharuAggarwalMD. June 2, 2024. X (Twitter).

Annals of Oncology. @Annals_Oncology. June 4, 2024. X (Twitter).

Stephanie A Berg, DO. @bergsa83. June 3, 2024. X (Twitter).

Benjamin Besse, MD. @BenjaminBesseMD. June 2, 2024. X (Twitter).

Arifa Bibi, MD. @arifabibi5. June 3, 2024. X (Twitter).

M. Bolton. @5_utr. June 2, 2024. X (Twitter).

Darcy Burbage, DNP, RN, AOCN. @DarcyBurbage. June 4, 2024. X (Twitter).

Toni Okay. Choueiri, MD. @DrChoueiri. June 1, 2024. X (Twitter).

Toni Okay. Choueiri, MD. @DrChoueiri. June 1, 2024. X (Twitter).

Toni Okay. Choueiri, MD. @DrChoueiri. June 1, 2024. X (Twitter).

Marcelo Corassa, MD. @MarceloCorassa. Might 31, 2024. X (Twitter).

Dana-Farber Information. @DanaFarberNews. June 4, 2024. X (Twitter).

Dana-Farber’s Lowe Heart for Thoracic Oncology. @DFarberThoracic. June 5, 2024. X (Twitter).

Devika Das, MD, MSHQS. @DevikaDasMD. June 2, 2024. X (Twitter).

Albert Einstein School of Medication. @EinsteinMed. June 6, 2024. X (Twitter).

#FlorezLab. @Florez_Lab. June 3, 2024. X (Twitter).

#FlorezLab. @Florez_Lab. June 5, 2024. X (Twitter).

Narjust Florez, MD, FASCO. @NarjustFlorezMD. Might 31, 2024. X (Twitter).

Narjust Florez, MD, FASCO. @NarjustFlorezMD. June 1, 2024. X (Twitter).

Patrick Forde, MBBCH. @FordePatrick. June 2, 2024. X (Twitter).

The ICR. @ICR_London. June 1, 2024. X (Twitter).

Percy Lee MD. @PercyLeeMD. June 2, 2024. X (Twitter).

Mark Lewis, MD. @marklewismd. June 2, 2024. X (Twitter).

Christine Lovly, MD, PhD. @christine_lovly. Might 31, 2024. X (Twitter).

Joseph McCollom, DO. @realbowtiedoc. June 2, 2024. X (Twitter).

Omar Mian, MD, PhD. @DrOmarMian. June 2, 2024. X (Twitter).

Giannis Mountzios MD, MSc, PhD. @g_mountzios. Might 31, 2024. X (Twitter).

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP. @tnewsomdavis. June 2, 2024. X (Twitter).

Timothée Olivier, MD. @Timothee_MD. June 2, 2024. X (Twitter).

Sumanta Okay. Pal, MD, FASCO. @montypal. June 4, 2024. X (Twitter).

Antonio Passaro, MD. @APassaroMD. Might 31, 2024. X (Twitter).

Sandip Patel, MD. @PatelOncology. June 2, 2024. X (Twitter).

Nagashree Seetharamu, MD, MBBS. @NagashreeSeeth1. June 2, 2024. X (Twitter).

Eric Okay. Singhi, MD. @lungoncdoc. Might 31, 2024. X (Twitter).

Brendon M. Stiles, MD. @BrendonStilesMD. June 2, 2024. X (Twitter).

Paolo Tarantino. @PTarantinoMD. June 4, 2024. X (Twitter).

Benedikt Westphalen, MD. @BenWestphalen. June 2, 2024. X (Twitter).


Please enter your comment!
Please enter your name here

Share post:



More like this

Safesmiles | Residence | Oral Well being Basis

Join and obtain all the newest information and...

Why I really like rebounding – The Fitnessista

Sharing my ideas on rebounding and why it’s...

Thorne Debuts Discover Your Approach Marketing campaign With Karlie Kloss

New York-based Thorne introduced its Discover Your Approach...